Jennifer Marvin-Peek

14PUBLICATIONS
87CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 06, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

|Mar 30, 2026
Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatment.

Jennifer Marvin-Peek, Wei-Ying Jen, Farhad Ravandi

|Feb 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.

Jayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero

|Nov 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek

|Nov 05, 2025
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Sven Turkalj, Felix A Radtke, Bilyana Stoilova

Pageof 3

Frequent Collaborators

10 joint publications

Courtney D DiNardo

7 joint publications

Naval G Daver

6 joint publications

Nicholas J Short

5 joint publications

Hagop M Kantarjian